| 16-Bromoepiandrosterone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 16-Bromoepiandrosterone. | Investigational |
| 19-norandrostenedione | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 19-norandrostenedione. | Experimental, Illicit |
| 5-androstenedione | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 5-androstenedione. | Experimental, Illicit |
| Abciximab | Oxyphenbutazone may increase the anticoagulant activities of Abciximab. | Approved |
| Acebutolol | Oxyphenbutazone may decrease the antihypertensive activities of Acebutolol. | Approved |
| Aceclofenac | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Aceclofenac. | Approved |
| Acenocoumarol | Oxyphenbutazone may increase the anticoagulant activities of Acenocoumarol. | Approved |
| Acetylsalicylic acid | The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Oxyphenbutazone. | Approved, Vet Approved |
| Aclarubicin | Oxyphenbutazone may decrease the excretion rate of Aclarubicin which could result in a higher serum level. | Investigational |
| Adapalene | The risk or severity of adverse effects can be increased when Adapalene is combined with Oxyphenbutazone. | Approved |
| Alclometasone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alclometasone. | Approved |
| Aldosterone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Aldosterone. | Experimental |
| Alendronic acid | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alendronic acid. | Approved |
| Aliskiren | Oxyphenbutazone may decrease the antihypertensive activities of Aliskiren. | Approved, Investigational |
| Alprenolol | Oxyphenbutazone may decrease the antihypertensive activities of Alprenolol. | Approved, Withdrawn |
| Alprostadil | The therapeutic efficacy of Alprostadil can be decreased when used in combination with Oxyphenbutazone. | Approved, Investigational |
| Amcinonide | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Amcinonide. | Approved |
| Amikacin | Oxyphenbutazone may decrease the excretion rate of Amikacin which could result in a higher serum level. | Approved, Vet Approved |
| Amiloride | Oxyphenbutazone may decrease the antihypertensive activities of Amiloride. | Approved |
| Amrubicin | Oxyphenbutazone may decrease the excretion rate of Amrubicin which could result in a higher serum level. | Approved, Investigational |
| Ancrod | Oxyphenbutazone may increase the anticoagulant activities of Ancrod. | Investigational |
| Andrographolide | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with HMPL-004. | Investigational |
| Androstenedione | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with 4-Androstenedione. | Experimental, Illicit |
| Anecortave | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Anecortave. | Investigational |
| Anisodamine | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Anisodamine. | Investigational |
| annamycin | Oxyphenbutazone may decrease the excretion rate of annamycin which could result in a higher serum level. | Investigational |
| Antipyrine | The risk or severity of adverse effects can be increased when Antipyrine is combined with Oxyphenbutazone. | Approved |
| Antithrombin III human | Oxyphenbutazone may increase the anticoagulant activities of Antithrombin III human. | Approved |
| Apixaban | Oxyphenbutazone may increase the anticoagulant activities of Apixaban. | Approved |
| Apocynin | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Acetovanillone. | Investigational |
| Apramycin | Oxyphenbutazone may decrease the excretion rate of Apramycin which could result in a higher serum level. | Experimental, Vet Approved |
| Apremilast | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Apremilast. | Approved, Investigational |
| Arbekacin | Oxyphenbutazone may decrease the excretion rate of Arbekacin which could result in a higher serum level. | Approved |
| Ardeparin | Oxyphenbutazone may increase the anticoagulant activities of Ardeparin. | Approved, Withdrawn |
| Argatroban | Oxyphenbutazone may increase the anticoagulant activities of Argatroban. | Approved, Investigational |
| Arotinolol | Oxyphenbutazone may decrease the antihypertensive activities of Arotinolol. | Approved |
| Atenolol | Oxyphenbutazone may decrease the antihypertensive activities of Atenolol. | Approved |
| Azapropazone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Azapropazone. | Withdrawn |
| Azelastine | The risk or severity of adverse effects can be increased when Azelastine is combined with Oxyphenbutazone. | Approved |
| Azilsartan medoxomil | The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxyphenbutazone. | Approved |
| Balsalazide | Oxyphenbutazone may increase the nephrotoxic activities of Balsalazide. | Approved, Investigational |
| Becaplermin | Oxyphenbutazone may increase the anticoagulant activities of Becaplermin. | Approved, Investigational |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Beclomethasone dipropionate. | Approved, Investigational |
| Befunolol | Oxyphenbutazone may decrease the antihypertensive activities of Befunolol. | Experimental |
| Benazepril | The risk or severity of adverse effects can be increased when Benazepril is combined with Oxyphenbutazone. | Approved, Investigational |
| Bendroflumethiazide | The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Benoxaprofen | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Benoxaprofen. | Withdrawn |
| Beraprost | The therapeutic efficacy of Beraprost can be decreased when used in combination with Oxyphenbutazone. | Investigational |
| Betamethasone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Betamethasone. | Approved, Vet Approved |
| Betaxolol | Oxyphenbutazone may decrease the antihypertensive activities of Betaxolol. | Approved |
| Betulinic Acid | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Betulinic Acid. | Investigational |
| Bevantolol | Oxyphenbutazone may decrease the antihypertensive activities of Bevantolol. | Approved |
| Bimatoprost | The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Oxyphenbutazone. | Approved, Investigational |
| Bisoprolol | Oxyphenbutazone may decrease the antihypertensive activities of Bisoprolol. | Approved |
| Bivalirudin | Oxyphenbutazone may increase the anticoagulant activities of Bivalirudin. | Approved, Investigational |
| Bopindolol | Oxyphenbutazone may decrease the antihypertensive activities of Bopindolol. | Approved |
| Bromfenac | The risk or severity of adverse effects can be increased when Bromfenac is combined with Oxyphenbutazone. | Approved |
| Bucillamine | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Bucillamine. | Investigational |
| Bucindolol | Oxyphenbutazone may decrease the antihypertensive activities of Bucindolol. | Investigational |
| Budesonide | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Budesonide. | Approved |
| Bufuralol | Oxyphenbutazone may decrease the antihypertensive activities of Bufuralol. | Experimental, Investigational |
| Bumetanide | Oxyphenbutazone may decrease the diuretic activities of Bumetanide. | Approved |
| Bupranolol | Oxyphenbutazone may decrease the antihypertensive activities of Bupranolol. | Approved |
| Candesartan | The risk or severity of adverse effects can be increased when Candesartan is combined with Oxyphenbutazone. | Approved |
| Candoxatril | The risk or severity of adverse effects can be increased when Candoxatril is combined with Oxyphenbutazone. | Experimental |
| Captopril | The risk or severity of adverse effects can be increased when Captopril is combined with Oxyphenbutazone. | Approved |
| Carboprost Tromethamine | The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Carprofen | The risk or severity of adverse effects can be increased when Carprofen is combined with Oxyphenbutazone. | Approved, Vet Approved, Withdrawn |
| Carteolol | Oxyphenbutazone may decrease the antihypertensive activities of Carteolol. | Approved |
| Carvedilol | Oxyphenbutazone may decrease the antihypertensive activities of Carvedilol. | Approved, Investigational |
| Castanospermine | The risk or severity of adverse effects can be increased when Castanospermine is combined with Oxyphenbutazone. | Experimental |
| Celecoxib | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Celecoxib. | Approved, Investigational |
| Celiprolol | Oxyphenbutazone may decrease the antihypertensive activities of Celiprolol. | Approved, Investigational |
| Certoparin | Oxyphenbutazone may increase the anticoagulant activities of Certoparin. | Approved |
| Chloroquine | The risk or severity of adverse effects can be increased when Chloroquine is combined with Oxyphenbutazone. | Approved, Vet Approved |
| Chlorothiazide | The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxyphenbutazone. | Approved, Vet Approved |
| Chlorthalidone | The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Cholestyramine | Cholestyramine can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Choline magnesium trisalicylate | The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Oxyphenbutazone. | Approved |
| Ciclesonide | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ciclesonide. | Approved, Investigational |
| Cilazapril | The risk or severity of adverse effects can be increased when Cilazapril is combined with Oxyphenbutazone. | Approved |
| Cinoxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Cinoxacin. | Approved, Withdrawn |
| Ciprofloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Ciprofloxacin. | Approved, Investigational |
| Citric Acid | Oxyphenbutazone may increase the anticoagulant activities of Citric Acid. | Nutraceutical, Vet Approved |
| Clobetasol | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clobetasol. | Investigational |
| Clobetasol propionate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clobetasol propionate. | Approved |
| Clocortolone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clocortolone. | Approved |
| Clodronic Acid | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clodronate. | Approved, Investigational, Vet Approved |
| Clonixin | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clonixin. | Approved |
| Cloprostenol | The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Oxyphenbutazone. | Vet Approved |
| Colesevelam | Colesevelam can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Colestipol | Colestipol can cause a decrease in the absorption of Oxyphenbutazone resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Cortisone acetate. | Approved |
| Curcumin | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Curcumin. | Investigational |
| Cyclosporine | Oxyphenbutazone may increase the nephrotoxic activities of Cyclosporine. | Approved, Investigational, Vet Approved |
| D-Limonene | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with D-Limonene. | Investigational |
| Dabigatran etexilate | Oxyphenbutazone may increase the anticoagulant activities of Dabigatran etexilate. | Approved |
| Dalteparin | Oxyphenbutazone may increase the anticoagulant activities of Dalteparin. | Approved |
| Danaparoid | Oxyphenbutazone may increase the anticoagulant activities of Danaparoid. | Approved, Withdrawn |
| Darexaban | Oxyphenbutazone may increase the anticoagulant activities of Ym150. | Investigational |
| Daunorubicin | Oxyphenbutazone may decrease the excretion rate of Daunorubicin which could result in a higher serum level. | Approved |
| Deferasirox | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Deferasirox. | Approved, Investigational |
| Desirudin | Oxyphenbutazone may increase the anticoagulant activities of Desirudin. | Approved |
| Desmopressin | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desmopressin. | Approved |
| Desoximetasone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desoximetasone. | Approved |
| Desoxycorticosterone acetate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desoxycorticosterone acetate. | Approved |
| Desoxycorticosterone Pivalate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desoxycorticosterone Pivalate. | Experimental, Vet Approved |
| Dexamethasone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Dexamethasone. | Approved, Investigational, Vet Approved |
| Dexamethasone isonicotinate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Dexamethasone isonicotinate. | Vet Approved |
| Dexketoprofen | The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Oxyphenbutazone. | Approved |
| Dextran | Oxyphenbutazone may increase the anticoagulant activities of Dextran. | Approved, Vet Approved |
| Dextran 40 | Oxyphenbutazone may increase the anticoagulant activities of Dextran 40. | Approved |
| Dextran 70 | Oxyphenbutazone may increase the anticoagulant activities of Dextran 70. | Approved |
| Dextran 75 | Oxyphenbutazone may increase the anticoagulant activities of Dextran 75. | Approved |
| Diclofenac | The risk or severity of adverse effects can be increased when Diclofenac is combined with Oxyphenbutazone. | Approved, Vet Approved |
| Dicoumarol | Oxyphenbutazone may increase the anticoagulant activities of Dicoumarol. | Approved |
| Diflorasone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Diflorasone. | Approved |
| Diflunisal | The risk or severity of adverse effects can be increased when Diflunisal is combined with Oxyphenbutazone. | Approved |
| Difluocortolone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Difluocortolone. | Approved |
| Difluprednate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Difluprednate. | Approved |
| Digoxin | The serum concentration of Digoxin can be increased when it is combined with Oxyphenbutazone. | Approved |
| Dihydrostreptomycin | Oxyphenbutazone may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. | Vet Approved |
| Dinoprost | The therapeutic efficacy of Dinoprost can be decreased when used in combination with Oxyphenbutazone. | Investigational |
| Dinoprost Tromethamine | The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Oxyphenbutazone. | Approved, Vet Approved |
| Dinoprostone | The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Doxorubicin | Oxyphenbutazone may decrease the excretion rate of Doxorubicin which could result in a higher serum level. | Approved, Investigational |
| Drospirenone | Oxyphenbutazone may increase the hyperkalemic activities of Drospirenone. | Approved |
| Droxicam | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Droxicam. | Approved |
| Duvelisib | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Duvelisib. | Investigational |
| E-6201 | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with E6201. | Investigational |
| Ebselen | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ebselen. | Investigational |
| Edetic Acid | Oxyphenbutazone may increase the anticoagulant activities of Edetic Acid. | Approved, Vet Approved |
| Edoxaban | Oxyphenbutazone may increase the anticoagulant activities of Edoxaban. | Approved |
| Enalapril | The risk or severity of adverse effects can be increased when Enalapril is combined with Oxyphenbutazone. | Approved, Vet Approved |
| Enalaprilat | The risk or severity of adverse effects can be increased when Enalaprilat is combined with Oxyphenbutazone. | Approved |
| Enoxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Enoxacin. | Approved |
| Enoxaparin | Oxyphenbutazone may increase the anticoagulant activities of Enoxaparin. | Approved |
| Epirizole | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Epirizole. | Approved |
| Epirubicin | Oxyphenbutazone may decrease the excretion rate of Epirubicin which could result in a higher serum level. | Approved |
| Eplerenone | Oxyphenbutazone may decrease the antihypertensive activities of Eplerenone. | Approved |
| Epoprostenol | The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Eprosartan | The risk or severity of adverse effects can be increased when Eprosartan is combined with Oxyphenbutazone. | Approved |
| Equilenin | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Equilenin. | Experimental |
| Equilin | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Equilin. | Approved |
| Esmolol | Oxyphenbutazone may decrease the antihypertensive activities of Esmolol. | Approved |
| Estrone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Estrone. | Approved |
| Estrone sulfate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Estrone sulfate. | Approved |
| Etacrynic acid | Oxyphenbutazone may decrease the diuretic activities of Etacrynic acid. | Approved |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Oxyphenbutazone. | Approved, Investigational |
| Ethyl biscoumacetate | Oxyphenbutazone may increase the anticoagulant activities of Ethyl biscoumacetate. | Withdrawn |
| Etidronic acid | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etidronic acid. | Approved |
| Etodolac | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etodolac. | Approved, Investigational, Vet Approved |
| Etofenamate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etofenamate. | Approved |
| Etoricoxib | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etoricoxib. | Approved, Investigational |
| Evening primrose oil | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Evening primrose oil. | Approved |
| exisulind | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with exisulind. | Investigational |
| Fenbufen | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fenbufen. | Approved |
| Fenoprofen | The risk or severity of adverse effects can be increased when Fenoprofen is combined with Oxyphenbutazone. | Approved |
| Fenprostalene | The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Oxyphenbutazone. | Vet Approved |
| Fleroxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Fleroxacin. | Approved |
| Floctafenine | The risk or severity of adverse effects can be increased when Floctafenine is combined with Oxyphenbutazone. | Approved, Withdrawn |
| fluasterone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with fluasterone. | Investigational |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fludrocortisone. | Approved |
| Fluindione | Oxyphenbutazone may increase the anticoagulant activities of Fluindione. | Investigational |
| Flumequine | Oxyphenbutazone may increase the neuroexcitatory activities of Flumequine. | Withdrawn |
| Flumethasone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flumethasone. | Approved, Vet Approved |
| Flunisolide | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flunisolide. | Approved, Investigational |
| Flunixin | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flunixin. | Vet Approved |
| Fluocinolone Acetonide | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluocinolone Acetonide. | Approved, Investigational, Vet Approved |
| Fluocinonide | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluocinonide. | Approved, Investigational |
| Fluocortolone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluocortolone. | Approved, Withdrawn |
| Fluorometholone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluorometholone. | Approved |
| Fluprednidene | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluprednidene. | Approved, Withdrawn |
| Fluprednisolone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluprednisolone. | Approved |
| Fluprostenol | The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Oxyphenbutazone. | Vet Approved |
| Flurandrenolide | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Flurandrenolide. | Approved |
| Flurbiprofen | The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Oxyphenbutazone. | Approved, Investigational |
| Fluticasone furoate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluticasone furoate. | Approved |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluticasone Propionate. | Approved |
| Folic Acid | The therapeutic efficacy of Folic Acid can be decreased when used in combination with Oxyphenbutazone. | Approved, Nutraceutical, Vet Approved |
| Fondaparinux | Oxyphenbutazone may increase the anticoagulant activities of Fondaparinux. | Investigational |
| Fondaparinux sodium | Oxyphenbutazone may increase the anticoagulant activities of Fondaparinux sodium. | Approved, Investigational |
| Forasartan | The risk or severity of adverse effects can be increased when Forasartan is combined with Oxyphenbutazone. | Experimental |
| Formestane | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Formestane. | Approved, Investigational, Withdrawn |
| Fosinopril | The risk or severity of adverse effects can be increased when Fosinopril is combined with Oxyphenbutazone. | Approved |
| Framycetin | Oxyphenbutazone may decrease the excretion rate of Framycetin which could result in a higher serum level. | Approved |
| Furosemide | Oxyphenbutazone may decrease the diuretic activities of Furosemide. | Approved, Vet Approved |
| Gabexate | Oxyphenbutazone may increase the anticoagulant activities of Gabexate. | Investigational |
| Garenoxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Garenoxacin. | Investigational |
| Gatifloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Gatifloxacin. | Approved, Investigational |
| Gemeprost | The therapeutic efficacy of Gemeprost can be decreased when used in combination with Oxyphenbutazone. | Approved, Withdrawn |
| Gemifloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Gemifloxacin. | Approved, Investigational |
| Geneticin | Oxyphenbutazone may decrease the excretion rate of Geneticin which could result in a higher serum level. | Experimental |
| Gentamicin | Oxyphenbutazone may decrease the excretion rate of Gentamicin which could result in a higher serum level. | Approved, Vet Approved |
| GENTAMICIN C1A | Oxyphenbutazone may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. | Experimental |
| Grepafloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Grepafloxacin. | Withdrawn |
| Haloperidol | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Haloperidol. | Approved |
| HE3286 | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with HE3286. | Investigational |
| Heparin | Oxyphenbutazone may increase the anticoagulant activities of Heparin. | Approved, Investigational |
| Higenamine | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Higenamine. | Investigational |
| Hydralazine | Oxyphenbutazone may decrease the antihypertensive activities of Hydralazine. | Approved |
| Hydrochlorothiazide | The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxyphenbutazone. | Approved, Vet Approved |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Hydrocortisone. | Approved, Vet Approved |
| Hydroflumethiazide | The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Hygromycin B | Oxyphenbutazone may decrease the excretion rate of Hygromycin B which could result in a higher serum level. | Vet Approved |
| Ibandronate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ibandronate. | Approved, Investigational |
| Ibuprofen | The risk or severity of adverse effects can be increased when Ibuprofen is combined with Oxyphenbutazone. | Approved |
| Ibuproxam | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ibuproxam. | Withdrawn |
| Icatibant | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Icatibant. | Approved |
| Idarubicin | Oxyphenbutazone may decrease the excretion rate of Idarubicin which could result in a higher serum level. | Approved |
| Idraparinux | Oxyphenbutazone may increase the anticoagulant activities of idraparinux. | Investigational |
| Iloprost | The therapeutic efficacy of Iloprost can be decreased when used in combination with Oxyphenbutazone. | Approved, Investigational |
| Imidapril | The risk or severity of adverse effects can be increased when Imidapril is combined with Oxyphenbutazone. | Investigational |
| Indapamide | The therapeutic efficacy of Indapamide can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Indenolol | Oxyphenbutazone may decrease the antihypertensive activities of Indenolol. | Withdrawn |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Oxyphenbutazone. | Approved, Investigational |
| Indoprofen | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Indoprofen. | Withdrawn |
| INNO-206 | Oxyphenbutazone may decrease the excretion rate of INNO-206 which could result in a higher serum level. | Investigational |
| Irbesartan | The risk or severity of adverse effects can be increased when Irbesartan is combined with Oxyphenbutazone. | Approved, Investigational |
| Isoxicam | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Isoxicam. | Withdrawn |
| Istaroxime | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Istaroxime. | Investigational |
| Kanamycin | Oxyphenbutazone may decrease the excretion rate of Kanamycin which could result in a higher serum level. | Approved, Vet Approved |
| Kebuzone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Kebuzone. | Experimental |
| Ketoprofen | The risk or severity of adverse effects can be increased when Ketoprofen is combined with Oxyphenbutazone. | Approved, Vet Approved |
| Ketorolac | The risk or severity of adverse effects can be increased when Ketorolac is combined with Oxyphenbutazone. | Approved |
| Labetalol | Oxyphenbutazone may decrease the antihypertensive activities of Labetalol. | Approved |
| Landiolol | Oxyphenbutazone may decrease the antihypertensive activities of Aop200704. | Investigational |
| Latanoprost | The therapeutic efficacy of Latanoprost can be decreased when used in combination with Oxyphenbutazone. | Approved, Investigational |
| Leflunomide | The risk or severity of adverse effects can be increased when Leflunomide is combined with Oxyphenbutazone. | Approved, Investigational |
| Lepirudin | Oxyphenbutazone may increase the anticoagulant activities of Lepirudin. | Approved |
| Levobunolol | Oxyphenbutazone may decrease the antihypertensive activities of Levobunolol. | Approved |
| Levofloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Levofloxacin. | Approved, Investigational |
| Limaprost | The therapeutic efficacy of Limaprost can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Lisinopril | The risk or severity of adverse effects can be increased when Lisinopril is combined with Oxyphenbutazone. | Approved, Investigational |
| Lisofylline | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lisofylline. | Investigational |
| Lithium | The serum concentration of Lithium can be increased when it is combined with Oxyphenbutazone. | Approved |
| Lomefloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Lomefloxacin. | Approved |
| Lornoxicam | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lornoxicam. | Approved |
| Losartan | The risk or severity of adverse effects can be increased when Losartan is combined with Oxyphenbutazone. | Approved |
| Loxoprofen | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Loxoprofen. | Approved |
| Lubiprostone | The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Oxyphenbutazone. | Approved, Investigational |
| Lumiracoxib | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Lumiracoxib. | Approved, Investigational |
| Luprostiol | The therapeutic efficacy of Luprostiol can be decreased when used in combination with Oxyphenbutazone. | Vet Approved |
| Magnesium salicylate | The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Oxyphenbutazone. | Approved |
| Masoprocol | The risk or severity of adverse effects can be increased when Masoprocol is combined with Oxyphenbutazone. | Approved |
| ME-609 | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with ME-609. | Investigational |
| Meclofenamic acid | The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxyphenbutazone. | Approved, Vet Approved |
| Medrysone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Medrysone. | Approved |
| Mefenamic acid | The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Oxyphenbutazone. | Approved |
| Melengestrol | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Melengestrol. | Vet Approved |
| Meloxicam | The risk or severity of adverse effects can be increased when Meloxicam is combined with Oxyphenbutazone. | Approved, Vet Approved |
| Mesalazine | Oxyphenbutazone may increase the nephrotoxic activities of Mesalazine. | Approved |
| Metamizole | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Metamizole. | Withdrawn |
| Methotrexate | The serum concentration of Methotrexate can be increased when it is combined with Oxyphenbutazone. | Approved |
| Methyclothiazide | The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Methylprednisolone. | Approved, Vet Approved |
| Metipranolol | Oxyphenbutazone may decrease the antihypertensive activities of Metipranolol. | Approved |
| Metolazone | The therapeutic efficacy of Metolazone can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Metoprolol | Oxyphenbutazone may decrease the antihypertensive activities of Metoprolol. | Approved, Investigational |
| Metrizamide | Oxyphenbutazone may decrease the excretion rate of Metrizamide which could result in a higher serum level. | Approved |
| Misoprostol | The therapeutic efficacy of Misoprostol can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Mizoribine | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mizoribine. | Investigational |
| Moexipril | The risk or severity of adverse effects can be increased when Moexipril is combined with Oxyphenbutazone. | Approved |
| Mometasone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mometasone. | Approved, Vet Approved |
| Morniflumate | The risk or severity of adverse effects can be increased when Morniflumate is combined with Oxyphenbutazone. | Approved |
| Moxifloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Moxifloxacin. | Approved, Investigational |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxyphenbutazone. | Approved, Investigational |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxyphenbutazone. | Approved |
| Nabumetone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nabumetone. | Approved |
| Nadolol | Oxyphenbutazone may decrease the antihypertensive activities of Nadolol. | Approved |
| Nadroparin | Oxyphenbutazone may increase the anticoagulant activities of Nadroparin. | Approved |
| Nafamostat | Oxyphenbutazone may increase the anticoagulant activities of Nafamostat. | Approved, Investigational |
| Naftifine | The risk or severity of adverse effects can be increased when Naftifine is combined with Oxyphenbutazone. | Approved |
| Nalidixic Acid | Oxyphenbutazone may increase the neuroexcitatory activities of Nalidixic Acid. | Approved |
| Naproxen | The risk or severity of adverse effects can be increased when Naproxen is combined with Oxyphenbutazone. | Approved, Vet Approved |
| NCX 1022 | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with NCX 1022. | Investigational |
| Neamine | Oxyphenbutazone may decrease the excretion rate of Neamine which could result in a higher serum level. | Experimental |
| Nemonoxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Nemonoxacin. | Investigational |
| Neomycin | Oxyphenbutazone may decrease the excretion rate of Neomycin which could result in a higher serum level. | Approved, Vet Approved |
| Nepafenac | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nepafenac. | Approved |
| Netilmicin | Oxyphenbutazone may decrease the excretion rate of Netilmicin which could result in a higher serum level. | Approved |
| Niflumic Acid | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Niflumic Acid. | Approved |
| Nimesulide | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nimesulide. | Approved, Withdrawn |
| Nitroaspirin | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nitroaspirin. | Investigational |
| Norfloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Norfloxacin. | Approved |
| Ofloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Ofloxacin. | Approved |
| Oleoyl-estrone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Oleoyl estrone. | Investigational |
| Olmesartan | The risk or severity of adverse effects can be increased when Olmesartan is combined with Oxyphenbutazone. | Approved, Investigational |
| Olopatadine | The risk or severity of adverse effects can be increased when Olopatadine is combined with Oxyphenbutazone. | Approved |
| Olsalazine | Oxyphenbutazone may increase the nephrotoxic activities of Olsalazine. | Approved |
| Omacetaxine mepesuccinate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Omacetaxine mepesuccinate. | Approved |
| Omapatrilat | The risk or severity of adverse effects can be increased when Omapatrilat is combined with Oxyphenbutazone. | Investigational |
| Orgotein | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Orgotein. | Vet Approved |
| Otamixaban | Oxyphenbutazone may increase the anticoagulant activities of Otamixaban. | Investigational |
| Oxaprozin | The risk or severity of adverse effects can be increased when Oxaprozin is combined with Oxyphenbutazone. | Approved |
| Oxprenolol | Oxyphenbutazone may decrease the antihypertensive activities of Oxprenolol. | Approved |
| Pamidronate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pamidronate. | Approved |
| Paramethasone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Paramethasone. | Approved |
| Parecoxib | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Parecoxib. | Approved |
| Paromomycin | Oxyphenbutazone may decrease the excretion rate of Paromomycin which could result in a higher serum level. | Approved, Investigational |
| Pazufloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Pazufloxacin. | Investigational |
| Pefloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Pefloxacin. | Approved |
| Penbutolol | Oxyphenbutazone may decrease the antihypertensive activities of Penbutolol. | Approved, Investigational |
| Pentosan Polysulfate | Oxyphenbutazone may increase the anticoagulant activities of Pentosan Polysulfate. | Approved |
| Perindopril | The risk or severity of adverse effects can be increased when Perindopril is combined with Oxyphenbutazone. | Approved |
| Phenindione | Oxyphenbutazone may increase the anticoagulant activities of Phenindione. | Approved |
| Phenprocoumon | Oxyphenbutazone may increase the anticoagulant activities of Phenprocoumon. | Approved |
| Phenylbutazone | The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Oxyphenbutazone. | Approved, Vet Approved |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxyphenbutazone. | Approved, Investigational |
| Pindolol | Oxyphenbutazone may decrease the antihypertensive activities of Pindolol. | Approved |
| Pirarubicin | Oxyphenbutazone may decrease the excretion rate of Pirarubicin which could result in a higher serum level. | Investigational |
| Piretanide | Oxyphenbutazone may decrease the diuretic activities of Piretanide. | Experimental |
| Pirfenidone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pirfenidone. | Investigational |
| Piroxicam | The risk or severity of adverse effects can be increased when Piroxicam is combined with Oxyphenbutazone. | Approved, Investigational |
| Plicamycin | Oxyphenbutazone may decrease the excretion rate of Plicamycin which could result in a higher serum level. | Approved, Withdrawn |
| Polythiazide | The therapeutic efficacy of Polythiazide can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Practolol | Oxyphenbutazone may decrease the antihypertensive activities of Practolol. | Approved |
| Pralatrexate | The serum concentration of Pralatrexate can be increased when it is combined with Oxyphenbutazone. | Approved |
| Prasterone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prasterone. | Approved, Nutraceutical |
| Prasterone sulfate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with dehydroepiandrosterone sulfate. | Investigational |
| Prednicarbate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednicarbate. | Approved |
| Prednisolone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednisolone. | Approved, Vet Approved |
| Prednisone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednisone. | Approved, Vet Approved |
| Pregnenolone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pregnenolone. | Experimental |
| Probenecid | The serum concentration of Oxyphenbutazone can be increased when it is combined with Probenecid. | Approved |
| Propacetamol | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Propacetamol. | Approved |
| Propranolol | Oxyphenbutazone may decrease the antihypertensive activities of Propranolol. | Approved, Investigational |
| Prostaglandin B2 | The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Oxyphenbutazone. | Experimental |
| Prostaglandin G2 | The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Oxyphenbutazone. | Experimental |
| Prostalene | The therapeutic efficacy of Prostalene can be decreased when used in combination with Oxyphenbutazone. | Vet Approved |
| Protein C | Oxyphenbutazone may increase the anticoagulant activities of Protein C. | Approved |
| Protein S human | Oxyphenbutazone may increase the anticoagulant activities of Protein S human. | Approved |
| Protocatechualdehyde | Oxyphenbutazone may increase the anticoagulant activities of Protocatechualdehyde. | Approved |
| Prulifloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Prulifloxacin. | Investigational |
| PTC299 | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with PTC299. | Investigational |
| Puromycin | Oxyphenbutazone may decrease the excretion rate of Puromycin which could result in a higher serum level. | Experimental |
| Quinapril | The risk or severity of adverse effects can be increased when Quinapril is combined with Oxyphenbutazone. | Approved, Investigational |
| Quinethazone | The therapeutic efficacy of Quinethazone can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Ramipril | The risk or severity of adverse effects can be increased when Ramipril is combined with Oxyphenbutazone. | Approved |
| Rescinnamine | The risk or severity of adverse effects can be increased when Rescinnamine is combined with Oxyphenbutazone. | Approved |
| Resveratrol | The risk or severity of adverse effects can be increased when Resveratrol is combined with Oxyphenbutazone. | Experimental, Investigational |
| Reviparin | Oxyphenbutazone may increase the anticoagulant activities of Reviparin. | Approved |
| Ribostamycin | Oxyphenbutazone may decrease the excretion rate of Ribostamycin which could result in a higher serum level. | Approved |
| Rimexolone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Rimexolone. | Approved |
| Risedronate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Risedronate. | Approved, Investigational |
| Rivaroxaban | Oxyphenbutazone may increase the anticoagulant activities of Rivaroxaban. | Approved |
| Rofecoxib | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Rofecoxib. | Investigational, Withdrawn |
| Rosoxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Rosoxacin. | Approved |
| Sacubitril | The risk or severity of adverse effects can be increased when Sacubitril is combined with Oxyphenbutazone. | Approved |
| Salicylamide | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Salicylamide. | Approved |
| Salicylic acid | The risk or severity of adverse effects can be increased when Salicylic acid is combined with Oxyphenbutazone. | Approved, Vet Approved |
| Salsalate | The risk or severity of adverse effects can be increased when Salsalate is combined with Oxyphenbutazone. | Approved |
| Saprisartan | The risk or severity of adverse effects can be increased when Saprisartan is combined with Oxyphenbutazone. | Experimental |
| Saralasin | The risk or severity of adverse effects can be increased when Saralasin is combined with Oxyphenbutazone. | Investigational |
| Seratrodast | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Seratrodast. | Approved |
| Sisomicin | Oxyphenbutazone may decrease the excretion rate of Sisomicin which could result in a higher serum level. | Investigational |
| Sotalol | Oxyphenbutazone may decrease the antihypertensive activities of Sotalol. | Approved |
| SP1049C | Oxyphenbutazone may decrease the excretion rate of SP1049C which could result in a higher serum level. | Investigational |
| Sparfloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Sparfloxacin. | Approved |
| Spectinomycin | Oxyphenbutazone may decrease the excretion rate of Spectinomycin which could result in a higher serum level. | Approved, Vet Approved |
| Spirapril | The risk or severity of adverse effects can be increased when Spirapril is combined with Oxyphenbutazone. | Approved |
| Spironolactone | Oxyphenbutazone may decrease the antihypertensive activities of Spironolactone. | Approved |
| SRT501 | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with SRT501. | Investigational |
| Streptomycin | Oxyphenbutazone may decrease the excretion rate of Streptomycin which could result in a higher serum level. | Approved, Vet Approved |
| Streptozocin | Oxyphenbutazone may decrease the excretion rate of Streptozocin which could result in a higher serum level. | Approved |
| Sulfasalazine | Oxyphenbutazone may increase the nephrotoxic activities of Sulfasalazine. | Approved |
| Sulindac | The risk or severity of adverse effects can be increased when Sulindac is combined with Oxyphenbutazone. | Approved |
| Sulodexide | Oxyphenbutazone may increase the anticoagulant activities of Sulodexide. | Approved, Investigational |
| Sulprostone | The therapeutic efficacy of Sulprostone can be decreased when used in combination with Oxyphenbutazone. | Investigational |
| Suprofen | The risk or severity of adverse effects can be increased when Suprofen is combined with Oxyphenbutazone. | Approved, Withdrawn |
| Tacrolimus | Oxyphenbutazone may increase the nephrotoxic activities of Tacrolimus. | Approved, Investigational |
| Tafluprost | The therapeutic efficacy of Tafluprost can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Talniflumate | The risk or severity of adverse effects can be increased when Talniflumate is combined with Oxyphenbutazone. | Approved |
| Tasosartan | The risk or severity of adverse effects can be increased when Tasosartan is combined with Oxyphenbutazone. | Approved |
| Technetium Tc-99m etidronate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Technetium tc 99m etidronate. | Approved |
| Technetium Tc-99m medronate | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Technetium Tc-99m Medronate. | Approved |
| Telmisartan | The risk or severity of adverse effects can be increased when Telmisartan is combined with Oxyphenbutazone. | Approved, Investigational |
| Temafloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Temafloxacin. | Withdrawn |
| Temocapril | The risk or severity of adverse effects can be increased when Temocapril is combined with Oxyphenbutazone. | Experimental, Investigational |
| Tenofovir disoproxil | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tenofovir. | Approved, Investigational |
| Tenoxicam | The risk or severity of adverse effects can be increased when Tenoxicam is combined with Oxyphenbutazone. | Approved |
| Tepoxalin | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tepoxalin. | Vet Approved |
| Teriflunomide | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Teriflunomide. | Approved |
| Tiaprofenic acid | The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Oxyphenbutazone. | Approved |
| Tiludronic acid | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tiludronate. | Approved, Vet Approved |
| Timolol | Oxyphenbutazone may decrease the antihypertensive activities of Timolol. | Approved |
| Tinoridine | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tinoridine. | Investigational |
| Tixocortol | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tixocortol. | Approved |
| Tobramycin | Oxyphenbutazone may decrease the excretion rate of Tobramycin which could result in a higher serum level. | Approved, Investigational |
| Tolfenamic Acid | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tolfenamic Acid. | Approved |
| Tolmetin | The risk or severity of adverse effects can be increased when Tolmetin is combined with Oxyphenbutazone. | Approved |
| Torasemide | Oxyphenbutazone may decrease the diuretic activities of Torasemide. | Approved |
| Trandolapril | The risk or severity of adverse effects can be increased when Trandolapril is combined with Oxyphenbutazone. | Approved |
| Tranilast | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tranilast. | Approved, Investigational |
| Travoprost | The therapeutic efficacy of Travoprost can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Treprostinil | The risk or severity of adverse effects can be increased when Treprostinil is combined with Oxyphenbutazone. | Approved, Investigational |
| Triamcinolone | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Triamcinolone. | Approved, Vet Approved |
| Triamterene | Oxyphenbutazone may decrease the antihypertensive activities of Triamterene. | Approved |
| Trichlormethiazide | The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxyphenbutazone. | Approved, Vet Approved |
| Trovafloxacin | Oxyphenbutazone may increase the neuroexcitatory activities of Trovafloxacin. | Approved, Withdrawn |
| Unoprostone | The therapeutic efficacy of Unoprostone can be decreased when used in combination with Oxyphenbutazone. | Approved |
| Valdecoxib | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Valdecoxib. | Investigational, Withdrawn |
| Valrubicin | Oxyphenbutazone may decrease the excretion rate of Valrubicin which could result in a higher serum level. | Approved |
| Valsartan | The risk or severity of adverse effects can be increased when Valsartan is combined with Oxyphenbutazone. | Approved, Investigational |
| Vancomycin | The serum concentration of Vancomycin can be increased when it is combined with Oxyphenbutazone. | Approved |
| Warfarin | Oxyphenbutazone may increase the anticoagulant activities of Warfarin. | Approved |
| Ximelagatran | Oxyphenbutazone may increase the anticoagulant activities of Ximelagatran. | Approved, Investigational, Withdrawn |
| Zaltoprofen | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zaltoprofen. | Approved |
| Zileuton | The risk or severity of adverse effects can be increased when Zileuton is combined with Oxyphenbutazone. | Approved, Investigational, Withdrawn |
| Zoledronic acid | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zoledronic acid. | Approved |
| Zomepirac | The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zomepirac. | Withdrawn |
| Zorubicin | Oxyphenbutazone may decrease the excretion rate of Zorubicin which could result in a higher serum level. | Experimental |
